Leerink Partnrs Analysts Lift Earnings Estimates for AbbVie Inc. (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) – Research analysts at Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for AbbVie in a research note issued on Wednesday, August 28th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings of $12.11 per share for the year, up from their previous forecast of $11.55. The consensus estimate for AbbVie’s current full-year earnings is $10.87 per share. Leerink Partnrs also issued estimates for AbbVie’s FY2026 earnings at $13.41 EPS, FY2027 earnings at $15.03 EPS and FY2028 earnings at $16.24 EPS.

AbbVie (NYSE:ABBV) last released its earnings results on Thursday, July 25th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.08. The company had revenue of $14.46 billion for the quarter, compared to analysts’ expectations of $14.02 billion. AbbVie had a return on equity of 186.82% and a net margin of 9.71%. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.91 EPS.

Several other equities research analysts have also recently issued reports on ABBV. Piper Sandler raised their target price on shares of AbbVie from $196.00 to $209.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. Morgan Stanley upped their price target on AbbVie from $211.00 to $218.00 and gave the stock an “overweight” rating in a report on Monday, August 12th. Truist Financial reiterated a “buy” rating and issued a $210.00 price objective (up previously from $195.00) on shares of AbbVie in a report on Friday, July 26th. Cantor Fitzgerald restated an “overweight” rating and set a $200.00 price objective on shares of AbbVie in a report on Monday, August 5th. Finally, BMO Capital Markets boosted their target price on shares of AbbVie from $180.00 to $214.00 and gave the stock an “outperform” rating in a research report on Friday, July 19th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $191.64.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $195.24 on Friday. The company has a debt-to-equity ratio of 7.93, a quick ratio of 0.83 and a current ratio of 0.94. The stock has a market cap of $344.77 billion, a PE ratio of 57.93, a price-to-earnings-growth ratio of 2.49 and a beta of 0.64. AbbVie has a one year low of $135.85 and a one year high of $198.30. The business’s fifty day moving average price is $180.46 and its two-hundred day moving average price is $173.62.

Hedge Funds Weigh In On AbbVie

A number of hedge funds have recently added to or reduced their stakes in ABBV. Fairway Wealth LLC acquired a new position in AbbVie in the 2nd quarter valued at $26,000. Ridgewood Investments LLC acquired a new position in shares of AbbVie during the 2nd quarter worth about $27,000. Vermillion & White Wealth Management Group LLC bought a new stake in AbbVie during the 4th quarter valued at approximately $26,000. IFS Advisors LLC acquired a new position in shares of AbbVie during the first quarter worth approximately $36,000. Finally, Redmont Wealth Advisors LLC acquired a new position in AbbVie during the 1st quarter valued at $37,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Activity at AbbVie

In other news, Chairman Richard A. Gonzalez sold 66,500 shares of AbbVie stock in a transaction on Monday, August 5th. The stock was sold at an average price of $186.52, for a total transaction of $12,403,580.00. Following the transaction, the chairman now owns 446,599 shares in the company, valued at $83,299,645.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Chairman Richard A. Gonzalez sold 66,500 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $186.52, for a total transaction of $12,403,580.00. Following the transaction, the chairman now directly owns 446,599 shares of the company’s stock, valued at $83,299,645.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Richard A. Gonzalez sold 282,845 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $175.00, for a total transaction of $49,497,875.00. Following the completion of the sale, the chairman now owns 513,099 shares of the company’s stock, valued at approximately $89,792,325. The disclosure for this sale can be found here. 0.25% of the stock is owned by insiders.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, August 15th. Stockholders of record on Monday, July 15th were issued a dividend of $1.55 per share. The ex-dividend date of this dividend was Monday, July 15th. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.18%. AbbVie’s dividend payout ratio is currently 183.98%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.